id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
blsr-12243	Harry Shanmugam	Pharmaceutical Price-Gouging: An Analysis of Maryland's Efforts to Regulate Unconscionable Increases in the Prices of Generic Drugs	2020	15	.pdf	application/pdf	4395	209	49	Over the last decade, drug companies and industry groups have poured $2.3 billion into lobbying efforts in Washington.12 As a result, according to a joint report by the Yale School of Public Health and the Yale Law School, “the federal government has failed to take—and many policymakers have not even considered—meaningful steps to curb drug prices.”13 16 in a generic drug market, drug prices decrease by 20%, and yet, pharmaceutical companies report consistent barriers to entry and inhibitors to competition.38 The largest such barrier is the bloated nature of the FDA approval process for generics.	cache/blsr-12243.pdf	txt/blsr-12243.txt